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Exposure concentrations of chemicals in air,
food, water, soil, dust, or other media with
which populations are in contact are the dose
scales most commonly used when assessing
health effects for environmental or occupa-
tional pollutants. Yet, external exposure is
often only a rough estimate for internal expo-
sure delivered at the critical target in the
body. The latter is a more appropriate mea-
sure of dose for mechanism-based risk assess-
ments (1). For example, many chemicals
require metabolic conversion into chemically
active species before exhibiting toxicity, and
this conversion may be subject to saturation
at high doses (2–5). In the presence of sat-
urable activation or detoxification pathways,
the relationship between administered (exter-
nal) dose and delivered (internal) dose may be
nonlinear. This nonlinearity is of particular
concern when performing high-to-low-dose
extrapolation of the overall exposure–
response relationship. Indeed, a solution is to
measure internal biomarkers of exposure, but
such direct measurements may not be feasible
if the relevant biomarkers are not yet devel-
oped. In this case, modeling approaches can
be advocated as an alternative. Toxicokinetic
(TK) models, for example, are useful tools to
relate external exposures to internal measures
of dose. TK models describe the behavior of
chemicals in the body, e.g. the processes of
absorption, distribution, metabolism, and
elimination. Two main classes of TK models
have been developed: classical toxicokinetic
models and physiologically based toxico-
kinetic (PBTK) models. The development of
PBTK models has been particularly active
during the last 20 years, and their usefulness
for chemical risk assessments is now firmly
established (5–10). Several major chemical
risk assessments currently processed by the
U.S. Environmental Protection Agency
involve the use of PBTK models. 
The focus of PBTK modeling in risk
assessment to date has been essentially on
improving the scientific basis for extrapolat-
ing risk from animals to humans (11).
Before the introduction of PBTK models,
the key default assumption regarding inter-
species extrapolation was that animal expo-
sures could be converted to equivalent
human exposures by a surface area correc-
tion factor. However, several examples can
be found in the literature in which compara-
tive modeling of distribution and metabo-
lism in animals and humans has challenged
the use of simple surface area conversions for
interspecies extrapolations (12–15). The
ability to tailor the parameter values of
PBTK models to a particular animal species
offers, in theory, a firm basis for interspecies
extrapolation. In practice, for most PBTK
models some parameters remain difficult to
extrapolate across species. For metabolic
parameters, in particular, species-specific val-
ues may be difficult to obtain experimen-
tally. The “parallelogram approach” (16,17)
may provide partial answers to this question,
but parameters typically still need to be
adjusted through calibration of the model
with pharmacokinetic data (usually mea-
sured time courses of parent compound and
metabolites in biological media such as
exhaled air, blood, urine, etc.). 
If some uneasiness has been expressed
about the use of PBTK models (18), it was
essentially because of the lack of statistical
methods for calibrating them, i.e., for adjust-
ing their parameter values by taking toxicoki-
netic data into account. Another issue
gaining major attention in the scientific and
regulatory communities is population vari-
ability in toxicokinetic and metabolic
processes (9,19–27). Considering this vari-
ability and the uncertainty about many para-
meters difficult to measure accurately, using
fixed parameter values or presenting results
in the form of point estimates can be funda-
mentally misleading (28). Obviously, the
task of a correct statistical treatment of
PBTK models is daunting, as we are faced
with large nonlinear models, small data sets,
high uncertainty, and biological variability.
Until recently, there was no method for
rigourous statistical validation of PBTK
models. For example, to our knowledge, the
predictions made by such models were never
presented with meaningful confidence levels.
Consequently, it was impossible to decide
whether the fits were acceptable, the models
reasonable, and what confidence to place in
the results of extrapolation (29). 
In response to this challenge, our group
began to examine the statistical issues associ-
ated with the calibration and use of PBTK
models and to develop methods to solve them.
This article first briefly presents the structure
of classical TK and PBTK models. We then
discuss the issues of parameterization and cali-
bration of these models and describe a
Bayesian approach to their statistical analysis. 
Determining the relationship between an exposure and the resulting target tissue dose is a critical
issue encountered in quantitative risk assessment (QRA). Classical or physiologically based
toxicokinetic (PBTK) models can be useful in performing that task. Interest in using these models to
improve extrapolations between species, routes, and exposure levels in QRA has therefore grown
considerably in recent years. In parallel, PBTK models have become increasingly sophisticated.
However, development of a strong statistical foundation to support PBTK model calibration and use
has received little attention. There is a critical need for methods that address the uncertainties
inherent in toxicokinetic data and the variability in the human populations for which risk predictions
are made and to take advantage of a priori information on parameters during the calibration process.
Natural solutions to these problems can be found in a Bayesian statistical framework with the help
of computational techniques such as Markov chain Monte Carlo methods. Within such a
framework, we have developed an approach to toxicokinetic modeling that can be applied to
heterogeneous human or animal populations. This approach also expands the possibilities for
uncertainty analysis. We present a review of these efforts and other developments in these areas.
Appropriate statistical treatment of uncertainty and variability within the modeling process will
increase confidence in model results and ultimately contribute to an improved scientific basis for
the estimation of occupational and environmental health risks. Key words: Bayesian analysis,
hierarchical models, MCMC methods, toxicokinetic models, uncertainty, variability. — Environ
Health Perspect 108(suppl 5):883–893 (2000).
http://ehpnet1.niehs.nih.gov/docs/2000/suppl-5/883-893bernillon/abstract.html
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Toxicokinetic Models
A variety of TK models have been developed;
all are simplified representations of chemical
disposition within the human/animal organ-
ism. This section describes the structure and
characteristics of classical compartmental and
physiologically based models, which are the
main two classes of TK models found in the
literature. We then briefly present minimal
physiological models, which recently have
been proposed by several investigators.
Classical Compartmental (TK) Models 
In classical TK models, the body is repre-
sented by several connected compartments
(rarely more than three); each compartment
is a virtual space (i.e., compartments do not
necessarily reflect the anatomy of the species
of interest) within which the chemical is
assumed to be homogeneously distributed
(30). Chemical transfers between compart-
ments are described by a set of differential
equations. Typical parameters are compart-
ment volumes, exchange rates between them,
and clearance (elimination rate). The number
of compartments and the parameter values
are inferred from fitting the model to TK
data. A procedure commonly adopted when
using these models consists in first fitting a
simple, usually one-compartment model. If
the fit is unsatisfactory, another compartment
is added to the model, and so on, until an
acceptable fit is achieved. Parameter values
derived from the analysis of classical compart-
ments models are data dependent and are not
intended to represent actual physiological vol-
umes or flows in the organism (11). For
example, the volume of distribution of a par-
ticular compound can be much greater than
the volume of the body (this is the case for
chemicals with high affinities for tissue pro-
teins) (31). These models thus are commonly
referred as empirical or data-based models.
Classical compartmental models are reli-
able tools to predict various surrogates of dose
such as areas under the concentration–time
curve or the maximum concentration reached
in diverse biological media (e.g., exhaled air,
venous blood, urine) when the objective is to
interpolate from the current data. They are
widely used in pharmacokinetic studies to
investigate drug disposition in the body.
Nevertheless, given their lack of physiological
relevance, these models are not indicated to
extrapolate kinetic results between species,
exposure routes, or exposure conditions. For
these reasons, other modeling approaches,
including physiologically-based models, have
been investigated.
PBTK Models
In PBTK models, the body is subdivided into
a series of anatomical or physiological com-
partments that correspond to specific organs
(liver, kidney, lung) or lumped tissue and
organ groups (fat, richly perfused, and slowly
perfused tissues) (32–34). Tissues or organs
are lumped when they have, for example,
similar blood flow and fat content and when
partitioning of the substance of interest
between them can be considered homoge-
neous. Connections between compartments
represent the blood or lymphatic circulation
and chemical transfers between compart-
ments are described by mass balance differen-
tial equations. The time course of transport
and transformations of a chemical through
the various compartments can be simulated
via the resolution of the model’s set of equa-
tions for any given set of parameter values.
PBTK models include three types of parame-
ters: physiological parameters such as breath-
ing rate, blood flows, and tissue volumes;
physicochemical parameters, such as partition
coefficients that represent the relative solubil-
ity of a chemical in specific tissue; and bio-
chemical parameters describing, for example,
metabolic processes. The number of compart-
ments to be included in the model depends
on the objective of the study and on the pos-
sible mode(s) of action and site(s) of toxicity
of the chemical studied. In most cases, the
kidney or the liver are usually individualized
when they are major organs of elimination
and/or metabolism. Other organs are also
individualized (e.g. bone marrow, brain,
bone) when they are known sites of metabo-
lism, storage, or toxicity. In many applica-
tions, distribution among compartments is
supposed to be limited by perfusion; once in
a compartment, the chemical distributes
instantaneously and homogeneously through-
out the entire volume of the compartment.
More complex models describing the diffu-
sion of the compound in subcompartments
representing vascular, interstitial, and intra-
cellular spaces (diffusion-limited models)
have also been developed (35–37).
Figure 1 illustrates a general four-
compartment PBTK model for volatile
chemicals, which we used to study tetra-
chloroethylene (TETRA) kinetics in humans
(38,39). In this model, TETRA distribution
among the four compartments (well-perfused
tissues, poorly perfused tissues, fat, liver) is
supposed to be limited by blood perfusion, as
is often the case for apolar solvents. TETRA
absorption is supposed to occur by inhalation;
elimination takes place by exhalation and
metabolism. The only metabolically active
compartment included in the model is the
liver. TETRA primary metabolism is described
by a saturable Michaelis-Menten mechanism.
This model encloses 15 parameters.
Toxic effects induced by exposure to
chemicals are commonly observed during
experimental animal studies under conditions
of exposure different than typical human
occupational or environmental exposures.
PBTK models are promising tools to solve
some of the critical extrapolation issues
encountered in chemical risk assessments
(6,11,32,33,40–42):
• for example, dose extrapolation can auto-
matically be achieved with a PBTK model
assuming the model correctly captures the
linear and nonlinear dynamics involved in
the transport and metabolism of the
compound studied.
• Interspecies extrapolation is resolved by
assuming that the model structure is cor-
rect for two or more species (the TETRA
model described above, for example, is
reasonable for any mammal). Simply
changing parameters to values specific to
the species of interest operates the
extrapolation.
• Interroute (of exposure) extrapolations
can be performed. The model presented
above (Figure 1) has only one route of
entry, the lung; it is possible to simulate
intravenous injection by imposing
increase in venous blood concentration at
any time or by an explicit additional
equation; ingestion has been modeled
with such models as a direct infusion into
the liver compartment or with additional
compartments describing the gastro-
intestinal tract; dermal absorption has also
been modeled by addition of a skin
compartment (43,44).
PBTK models can explain the toxico-
kinetic behavior of the compound studied
under special conditions in humans such as
physical activity (45) or in specific targeted
populations (children, aged, obese) by simply
changing the values of some physiological
parameters. In addition, these models are
Figure 1. Schematic representation of a PBTK model
used for distribution and metabolism of TETRA (38). Q,
blood flows; V, compartment volumes; P, partition coeffi-
cients; VPR, ventilation over perfusion ratio; Vmax, maxi-
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attractive when modeling complex situations
such as developmental toxicity (36,46–52);
unusual exposure scenarios such as delayed
exposure of a nursing infant due to the
mother’s inhalation exposure can also be
addressed (53,54). 
The above properties of PBTK models
contribute to the development of more accu-
rate estimates of risk. PBTK modeling tech-
niques are now well developed. Nevertheless,
such models involve a large number of para-
meters (typically more than 20), each of
which is subject to some degree of uncer-
tainty and variability, which are translated
into PBTK model outputs. It is thus neces-
sary to consider the statistical issues raised by
such complexity. 
Minimal Physiological Models
Minimal (or reduced) physiological models
are PBTK models in which some of the com-
partments (e.g., poorly and well-perfused tis-
sues) have been lumped into a single central
compartment. Reducing the number of
compartments is a way to simplify the cali-
bration process while partly preserving the
model’s physiological character. In the case
of benzene, it has been shown that a reduced
three-compartment PBPK model can be a
good alternative to a five-compartment
PBPK model (23).
Figure 2 presents a minimal physiologi-
cal TK model of TETRA kinetics in the
human. TETRA kinetics in blood and
exhaled air are described by a three-compart-
ment TK model linked to a one-compart-
ment submodel for the main TETRA
metabolite, trichloroacetic acid (TCA) (55).
In the model, TETRA enters the body by
pulmonary exchange, modeled by first-order
transfers between air and the central com-
partment. TETRA venous blood concentra-
tions are assumed to be predicted by the
central compartment concentrations. The
second and third compartments are a priori
supposed to represent fat and muscles,
respectively. Metabolism of TETRA is
assumed to take place in the central com-
partment and is described by a linear
process. A fraction of metabolized TETRA
leads to TCA; the rest is made of the other
TETRA metabolites. TCA is formed from
TETRA metabolism but also from endoge-
nous background reactions. Urinary elimi-
nation of TCA is assumed to follow
first-order kinetics. 
Reduced PBTK models may be promising
tools to analyze data when many subjects are
involved. Recently, Fanning (56) used a
reduced PBTK model to analyze benzene
kinetics data from a cohort of 60 Chinese
workers. In that model, the human body was
divided into three compartments: a central
compartment, fat, and liver. Thomaseth and
Salvan (57) consider a minimal physiological
model to describe long-term kinetics of tetra-
chlorodibenzo-p-dioxin in human tissues
using data from a cohort of 359 subjects.
These examples simply illustrate that, as
with any modeling exercise, the development
of a toxicokinetic model must be guided pri-
marily by the question raised and the data
available to deal with it.
Statistical Considerations
PBTK models are considered an effective
means to predict target tissue dose, in particular
because of the large amount of a priori infor-
mation available in the literature on their
parameters. Nevertheless, calibration of TK
models, even when they are physiologically
based, is hardly feasible using only a priori
information. We mean by calibration the
allocation of appropriate values to model
parameters to enable that model to behave
like the system it represents. In fact, even
though reference values can be found in the
literature for physiological parameters such as
organ volumes or blood flows, experience has
shown that the calibration of virtually all
PBTK models requires estimation of some
parameters (in particular those describing
metabolism) using experimental TK data.
Such data typically consist of measured par-
ent and/or metabolite amounts or concentra-
tions from various sites in the body (e.g.,
blood, exhaled air, urine) at various times fol-
lowing the beginning of a controlled exposure
to the chemical studied. 
We address, in the following subsections,
the parameterization of TK models, their cali-
bration, and finally, the predictive use of
these models.
Parameterization 
It is first necessary to pay careful attention to
model parameterization (i.e., to definition of
the model parameters) to facilitate their sub-
sequent estimation. Many parameters of a
toxicokinetic model (e.g., cardiac output,
organ volumes, maximum rate of metabo-
lism) tend to be correlated to some measure
of body size. Furthermore, some parameters
are correlated to each other (e.g., organ blood
flows with cardiac output). Neglecting those
correlations might lead to unrealistic physio-
logical properties of the model, particularly
when a distribution of behaviors is computed
(e.g., through Monte Carlo simulations). It is
traditional to implement an a priori deter-
ministic modeling of known physiological
dependencies between parameters by using
scaling functions and allometric (related-to-
size) relationships (58–63). For example, vol-
umes can be parameterized as fractions of the
lean body weight, flows as fractions of cardiac
output, and the maximum rate of metabolism
in the liver as a power function of lean body
weight. Not all parameters need to be scaled.
Unfortunately, there is no unique way to
implement scaling, and there does not appear
to be a rigorous foundation for any particular
choice so far in the literature. We assert that
covariate modeling should be guided by sta-
tistical considerations, as it is essentially a
regression problem, but this is a research
topic still to be explored.
Another problem that can be solved
through proper parameterization is parameter
identifiability. Identifiability characterizes
parameters for which reasonable estimates can
be obtained given experimental data (64–66).
Parameter identifiability is a critical issue in
compartmental kinetic modeling (67,68) and
should be examined before any attempt to
calibrate the model. Two types of identifiabil-
ity can be distinguished: structural and statis-
tical. The first is concerned with the formal
model’s equations and parameters, i.e. the
structure of the model. As an example, con-
sider the following model equation:
y = α × β × x, [1]
where α and β are unknown parameters to
estimate from observations of x and y. If nei-
ther α nor β appears separately in another
model-defining equation, α and β will not be
separately identifiable whatever the data used
to estimate them. Each one can take an infinite
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Figure 2. Schematic representation of a linear three-
compartment model used for distribution and metabo-
lism of TETRA and distribution of TCA by Bernillon et al.
(55). The model considers 14 parameters; symbols are:
Falv, alveolar flow; V, volumes; K, rates of distribution
from central to peripheral compartments; P, partition
coefficients; CLTetra, TETRA metabolic clearance;
BgdTCA, endogenous TCA formation rate; KelTCA, TCA
elimination rate; fTCA, fraction of metabolized TETRA
leading to TCA; fTCA_u, fraction of total eliminated TCA
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and unbounded number of values. Only their
product α × β can be reasonably estimated. α
and β can become identifiable if an informa-
tive prior has been specified for one of them in
a Bayesian context. Structural identifiability
can also be ensured by an adequate parame-
terization. Structural nonidentifiability was
encountered when calibrating the minimal
PBTK model for TETRA kinetics depicted in
Figure 2, with the two couples of parameters
(Pp1c , Vperiph1) and (Pp2, Vperiph2). Their prod-
ucts, Pp1c × Vperiph1 and Pp2c × Vperiph2, were
thus the parameters actually estimated.
Putting separate priors on Pp1c, Vperiph1, Pp2c,
and Vperiph2 was another option we could have
taken. The second type of identifiability,
called data-conditioned, or statistical, charac-
terizes parameters that can be precisely esti-
mated. For a parameter estimate, precision is
the inverse of uncertainty, and we treat this
question extensively in the next section. In
essence, statistical identifiability is ensured by
either adequate data to estimate all model
parameters or, in a Bayesian context, suffi-
cient prior information to constrain those
parameters (69). In a TK context, for exam-
ple, statistical nonidentifiability may be
encountered when experimental data do not
include observations during or close to the
absorption phase. In that case, the parameters
characterizing absorption will be poorly esti-
mated given that data set. In a way, statistical
identifiability is a milder form of structural
identifiability that does not require reparame-
terization to be treated. Reparameterization
can still be useful in case of statistical identifi-
ability, as it can hasten computations during
the calibration process.
Calibration, Uncertainty, and Variability
Uncertainty and variability in the TK
parameter estimates affect potentially all TK
model predictions (e.g., estimates of tissue
doses); it is necessary to assess both to make
predictions useful for risk analysts and deci-
sionmakers. This helps to determin the con-
fidence to place in those predictions, to
assess the range of internal dose likely to
occur within the population for which the
risk is being evaluated, and finally, to weight
the decisions on the basis of TK model
predictions (21,26). 
It is important to distinguish between
uncertainty and variability. Variability typi-
cally refers to differences in the values of
model parameters among individuals (inter-
individual variability) or across time within a
given individual (intraindividual variability).
Variability may stem from genetic differences,
lifestyles, physiological status, age, etc. (26).
Uncertainty, on the other hand, essentially is a
result of lack of knowledge (70) and may have
various sources. TK parameters are known
only with finite precision. The use of
standard values, such as those in the
International Commission on Radiological
Protection report (71), tend to give a false
impression of precision for physiological
parameter values (and thus for model predic-
tions). At best, such standard or default val-
ues are approximate values of the average for
a human population. There always will be
uncertainty about their true value for a par-
ticular group of animals or humans, and even
more for a particular individual exposed
(from which TK data may be available). In
addition, most chemical-specific parameters
tend to be imprecise; i.e., they may have
been measured in vitro rather than in vivo or
they may be accessible only after fitting a
model to TK data. Measurement errors on
the experimental data, sparseness of those,
and model simplifications or mispecifications
are translated into uncertainties in the para-
meter values determined by statistical fitting
to such data. Uncertainty may be reduced by
further experiments, the design of which can
be formally optimized (72,73), or by a better
understanding of the actual processes under
study.
Variability is inherent in animal and
human populations and cannot be reduced.
Both variability and uncertainty are usually
present in TK data. For example, each TK
data set is specific to the subjects studied and
extrapolating quantitative information from
such small groups to larger and different pop-
ulations requires careful consideration. In
fact, the primary interests of TK analyses
rarely lie in the toxicokinetics of the com-
pound studied in any particular individual
but resides instead in inferences both about
average TK behavior of substances in larger
groups (sensitive subpopulations, age groups,
whole-country population, etc.) and quantifi-
cation of the variability in such behavior. It is
necessary to take variability explicitely into
account within the calibration process. Data
pooling (i.e., treating averaged data values as
if they characterized a typical member of the
population) should be avoided, as it can
gravely distort the data (74,75).
Given the usual sparseness of TK data and
the number of parameters involved in a
PBTK model, conventional (e.g., uncon-
strained least square) parameter estimation is
generally not feasible. From a statistical point
of view, manually adjusting several parame-
ters is not scientifically acceptable. Neither is
the commonly used alternative, which con-
sists of statistically fitting only a subset of the
model parameters (assuming that the others
are exactly known and set to predefined refer-
ence values). It is difficult to arrive at a cor-
rect assessment of the uncertainty in model
predictions through such an approach.
Ignoring the uncertainty in a parameter value
implicitly ignores covariances between this
particular parameter and all others. This leads
to distortions in the entire covariance struc-
ture of parameter estimates (because covari-
ance between two parameters vanishes when
one is fixed) and finally, to an underestima-
tion of the uncertainty in model outputs
(76). As an illustration, consider a simple
two-dimensional case (Figure 3). Assume
that both parameter estimates, given the
data θ1, and θ2, are marginally (i.e., when
considered alone) normally distributed
(Figure 3A, C) and that they are highly cor-
related. The ellipse (Figure 3B) that outlines
the 95% joint confidence region for θ1 and
θ2 illustrates that covariance. A correct joint
estimation of θ1 and θ2 should give both
marginal and joint distributions closely
approximating those. However, setting θ1,
for convenience, to a fixed value, a, modifies
the structure of covariance between θ1 and
θ2, transforming the initial ellipse into a seg-
ment of line, s. The 95% confidence interval
for θ2, given θ1= a, now ranges from b to c
(panel C). The resulting distribution of θ2
estimates is much narrower than the correct
distribution and its mean may not even be
the same, which could later lead to biases
and underdispersion in predictions. In higher
(imagine 20) dimensions, the situation
would be considerably worse. 
Three points can be made here: First, fix-
ing the value of some parameters while
adjusting the other parameters is not satisfac-
tory unless there is no correlation between the
fixed and other parameters. Proving the
absence of such correlations is difficult and
amounts to first estimating all parameters
together (that is, considering all of them
uncertain). It is simpler and often more judi-
cious to stop at this first step and acknowl-
edge the complete covariance between all
parameters. Second, fixing θ1 for estimating
θ2 and then relaxing this constraint when
Figure 3. Illustration of covariance effects between two
parameter estimates. The correct joint and marginal
posteriors (i.e., data conditioned) are drawn as thick
lines. Setting θ1 to the value a before calibration leads
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performing predictions is incorrect, as the
covariance structure of θ1 and θ2 is disrupted
in the process and the resulting marginal dis-
tribution of θ2 is a conditional distribution
on the assumed known value of θ1. Third, in
most cases, it is not sufficient to check the
absence of sensitivity of some of the model
predictions to variations in θ1 values, because
what is important is the sensitivity of the
entire model calibration process to θ1.
Checking the sensitivity of some predictions
also raises a number of questions. For exam-
ple, which predictions should be checked?
And what is the scientific value of a calibra-
tion exercise which gives results only for a
particular application? Overall, ad hoc cali-
brations are an impediment to the general
applicability of PBTK models to various sce-
narios of exposures and effects.
Confidence in Model Predictions
Models are usually developed to obtain
predictions of various quantities of interest,
for example, the quantity of metabolites
formed for a given exposure to a specific com-
pound. Ignoring both variability and uncer-
tainty in model parameters renders TK model
predictions almost useless for risk assessment.
Several attempts have been made recently to
study the propagation of variability and
uncertainty in model parameters to model
predictions using Monte Carlo simulation
methods (13,23 24,27,77,78). These meth-
ods consist of: a) specifying a probability dis-
tribution for each model parameter; b )
sampling randomly each model parameter
from its specified distribution; c) running the
model using the sampled parameter values,
and computing various model predictions of
interest. Repeating steps b) and c) a large
number of times generates many different
values for the model predictions. Those val-
ues can be used as samples to create his-
tograms approximating the probability
distribution of any model prediction (79). 
Monte Carlo methods can be useful in
conducting global sensitivity analysis (25,80).
It is also possible with such methods to dis-
tinguish between variability and uncertainty
in model predictions when it is feasible to
separate the two for each model parameter
(81). The validity of Monte Carlo methods is
obviously highly dependent on the validity of
the assumed parameter distributions. These
distributions should adequately characterize
the variability and/or uncertainty and covari-
ance in the model parameters to predict the
range of TK behavior that could be expected
in a population and to determine the confi-
dence to place in model predictions (76).
Most Monte Carlo simulations of TK
models performed to date assumed for conve-
nience that all input parameters were inde-
pendent—partial exceptions can be found in
Farrar et al. (20), Bois et al. (21), and Smith
et al. (76). Most of the time this assumption
is not valid. Neglecting covariances typically
leads to very large confidence intervals in
model predictions, overestimating their actual
spread (19).
A better and more comprehensive
approach is to sample all parameter values
from their joint probability distribution (39).
Empirically specifying such a joint distribu-
tion is a difficult task, particularly when some
parameters have been estimated. In the next
section we describe how a Bayesian statistical
analysis can yield naturally such a joint distri-
bution (called joint posterior distribution).
Such an analysis leads to more relevant and
useful Monte Carlo simulations, taking into
account dependencies among all TK parame-
ters when computing model predictions. 
Multilevel Bayesian Analysis 
of TK Models
The above considerations led us to develop
and use multilevel models of uncertainty/vari-
ability in a Bayesian framework for the statis-
tical analysis of TK models. Those tools are
described in the following sections.
Multilevel Modeling
As stated above, inferring the TK behavior of
a compound in a population necessitates
extracting quantitative information from
individual TK data. A hierarchical structure
distinguishing individual and population lev-
els of variability is a convenient and efficient
way to perform that task. 
Population analyses were first introduced
in the context of pharmacokinetic studies for
drug development and evaluation (74,82,83).
Their advantages have long been discussed in
this context and a number of applications can
be found in the pharmacokinetic literature.
Yuh et al. (84) published a comprehensive
bibliography on methodological aspects and
applications of population models and a
detailed review of these methods can be
found in Davidian and Giltinian (85).
However, until recently, very little attention
has been paid to these approaches in a TK
context. Before the work of Bois et al. (38,86)
and Gelman et al. (39), the only attempt to
link population principles to TK modeling
was achieved by Droz et al. (87,88), but no
fitting to experimental data was performed in
this exercice.
The objective of population models is to
obtain from individual data a quantitative
description of the variability of the kinetic
behavior of a given compound within a pop-
ulation. Such a model is illustrated in
Figure 4. This hierarchical model has been
used for TETRA and benzene by Bois and
colleagues (38,39,86). The basic idea is that
the same kinetic model f can describe the
concentration–time profiles of the compound
and its metabolites for each individual, and
that the model parameters may vary from
individual to individual. Interindividual vari-
ability is then described by assuming that
each individual's parameter set ψi arises inde-
pendently from the other individual parame-
ter sets, from a common multivariate
probability distribution.
The model presented in Figure 4 has two
major components: the subject level and the
population level. At the subject level, chemical
concentrations are measured on each of the I
individuals studied (e.g., ni measurements for
individual i). Let: y1 = {yi1,yi 2, . . . , yin i }
denote the set of concentration measurements
made on individual i, and ti = {ti1,ti2,...,tini}
the set of their associated sampling times; the
kinetic model, denoted f, can predict concen-
tration–time profiles for given exposure char-
acteristics (E), individual TK parameters (ψi),
and physiological covariables (ϕi) (e.g., body
weight, age, sex, etc.). At this level, the mea-
surement error model is defined. Various error
models have been suggested to model the dif-
ferences between observed and model-pre-
dicted concentrations. One possible
lognormal error model frequently used for
concentration measurements is given by:
log yij = ln f (tij,Ei,ψi,ϕi) + εij, [2]
where the error terms εij are assumed to be
independent and normal random variables,
Environmental Health Perspectives • VOLUME 108 | SUPPLEMENT 5 | October 2000 887
Figure 4. Graph of a hierarchical population model
describing dependencies between groups of variables.
Three types of nodes are featured: square nodes repre-
sent variables for which the values are known by obser-
vation, such as y i or ϕ i ,  or were fixed by the
experimenters, such as Ei and ti; circle nodes represent
unknown variables such as ψi , σ2, µ, Σ; the triangle
represents the deterministic TK model ƒ. A plain arrow
between two nodes indicates a direct statistical depen-
dency between the variables of those nodes, a dashed
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with mean 0 and variance σ2. These error
terms may represent assay precision, model
mispecification, and/or random intraindivid-
ual variability in model parameters and
covariables. σ2 can be set to a fixed known
value (e.g., when the analytical error is
known and modeling error assumed negligi-
ble) or assumed to be a known function of
actual concentration in the biological sample;
it can also be estimated along with the other
model parameters.
At the population level, interindividual
variability is described by considering that the
vectors of individual TK parameters ψ1,
. . . , ψI are independent realizations from a
multivariate distribution, F, with mean vector
µ and scale matrix Σ:
ψi ∼ F(µ,Σ), i = 1, . . . , I. [3]
The population parameters, µ and Σ, are a
priori affected by uncertainty. 
Within the population framework, infor-
mation is gained on the average population
behavior, but at the same time information
on each subject is reinforced by borrowing
strength from the other subjects. The latter
effect is particularly useful when few observa-
tions are available per subject, which is typical
in pharmacokinetic and TK studies. This
framework is flexible and, for example, can be
extended to separate within-subject, between-
subject, and measurement uncertainty.
A number of methods have been proposed
to estimate kinetic parameters within a popu-
lation framework. They can be separated into
two broad classes, parametric and nonpara-
metric. In the parametric case, the shape of
the population distribution is assumed to be
known, and the population parameter values
are quantities to estimate (e.g., multivariate
normal distribution with unknown vector of
means and variance/covariance matrix).
Typically, assumed distributions for the popu-
lation distribution F include multivariate nor-
mal, lognormal, Student-t , or mixtures of
such distributions. In the nonparametric
approach, no assumption about the shape of
the population distribution is made, and the
entire distribution (both the shape and the
parameters) is estimated from the population
data (89–91). The parametric approach is the
most commonly used because the data are
often too sparse for nonparametric estimation. 
The above approaches rely typically on
maximum likelihood techniques (82,92,93)
or on Bayesian principles (94,95). Bayesian
approaches prove to be very efficient when
dealing with the complexities brought about
by the large number of parameters of the
hierarchical structure (a 10-parameter TK
model applied to 50 subjects leads to more
than 500 parameters to estimate) and by the
nonlinearities typically present in the subject-
specific kinetic models (94,95). They are
particularly appealing in the case of PBTK
models, as they allow prior physiological
information to be incorporated explicitely
into the analysis (39). 
The Bayesian Approach 
A Bayesian statistical analysis allows combina-
tion of two forms of information: prior
knowledge about parameter values drawn
from the scientific literature, and data from
TK experiments (96,97). In this section we
first present the general principles of Bayesian
statistical analyses and then we explain how
likelihood and prior distributions can be
elicited in the case of a population TK model;
then, using the Metropolis Hastings (MH)
sampler as an illustration, we explain how
Markov chain Monte Carlo (MCMC) algo-
rithms proceed, and finally, we illustrate how
inference and predictions can be made from
MCMC outputs.
General principles. In a Bayesian setting,
all model unknowns, θ, are considered ran-
dom variables. The probability distribution
of an unknown model is interpreted in terms
of degrees of belief about possible values of
that quantity. Before conducting an experi-
mental study, a prior probability distribu-
tion, p(θ) is constructed to reflect current
knowledge of θ. This prior distribution is
then updated using the data values, y, to
yield a posterior probability distribution of
model unknowns. Bayes’ theorem indicates
that the posterior probability distribution of
θ given y, p(θ|y), is proportional to the prod-
uct of the likelihood by the prior p(θ). In a
Bayesian framework, the likelihood of a par-
ticular data set, given an assumed model and
its parameter values, is the conditional prob-
ability distribution of the observed data,
p(y|θ). Bayes’ rule can be viewed as a formula
that shows how existing beliefs, formally
expressed as probability distributions, are
modified by new information (98):
p(θ|y) ∝ p(y|θ) × p(θ). [4]
All inferences about θ or a particular set of its
components follow from the posterior distrib-
ution p(θ|y): means, standard deviations
(SDs), quantiles, correlations, and marginal
distributions are obtainable by integration of
p(θ|y). In the case of the above population
TK model, model unknowns, θ, comprise the
individual TK parameter vectors ψi, i = 1,
. . . , I (denoted ψ in the following, for conve-
nience), the population parameter vector or
matrix, µ and Σ, and a variance term for the
measurement errors, σ2. Hence, Equation 4
takes the form:
p(ψ,µ,Σ,σ2|y) ∝ p(y|ψ,µ,Σ,σ2) × p(ψ,µ,Σ,σ2).
[5]
It is possible to rewrite Equation 5 as a
product of simpler conditional distributions,
considering the following arguments, which
are legitimate in any similar hierarchical
model. First, arguments of conditional inde-
pendence (99–101) allow us to simplify the
first term of the right side of Equation 5:
p(y|ψ,µ,Σ,σ2) = p(y|ψ,σ2). [6]
Second, assuming that the experimental
error variance is a priori independent of (ψ,
µ, Σ) (which is reasonable in most applica-
tions), and by the definition of conditional
probabilities, the second term of the right
side of Equation 5 can be written as:
p(ψ,µ,Σ,σ2) = p(ψ,µ,Σ) × p(σ2) 
= p(ψ|µ,Σ) × p(µ,Σ) × p(σ2), [7]
leading to the following expression for p(θ|y):
p(ψ,µ,Σ,σ2|y) ∝ p(y|ψ,σ2) ×
p(ψ|µ,Σ) × p(µ,Σ) × p(σ2); [8]
finally, µ and Σ are usually assumed to be a
priori independent, allowing the factorization
of p(µ, Σ): 
p(ψ,µ,Σ,σ2|y) ∝ p(y|ψ,σ2) ×
p(ψ|µ,Σ) × p(µ) × p(Σ) × p(σ2). [9]
Even though Equation 9 involves simpler
components than Equation 5, it is impossible
to obtain an analytical expression for p(θ|y),
in particular because of the nonlinear form of
the TK model. Until recently, this intractabil-
ity has been a strong impediment to practical
Bayesian analyses. Fortunately, the recent
advent of MCMC methods has alleviated a
number of these difficulties. These methods
are powerful tools to provide samples of para-
meter values from p(θ|y) even without knowl-
edge of the analytical expression of p(θ|y)
(102,103). They have largely contributed to
the recent proliferation of Bayesian analyses
in applied statistics. These methods require
the functional forms for p(y|ψ,σ2) (the likeli-
hood), p(ψ|µ,Σ) (the population model per
se), and p(µ), p(Σ), and p(σ2) (the priors). 
Specification of likelihood and prior
distributions. The choice of a likelihood
function embodies an error model and has
been discussed previously. For example, con-
sider the 15-parameter (K = 15) PBTK model
depicted in Figure 1 and the associated popu-
lation model in Figure 4 (38). This model
was calibrated using TETRA concentration
data measured in the exhaled air and venous
blood of I = 6 human volunteers exposed to
70 and 144 ppm of TETRA for 4 hr (104).
To specify a likelihood on the observed indi-
vidual concentrations (ni observations for
subject i ), it was assumed that analytical
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errors were independent and lognormally
distributed. The first-stage likelihood
p(y|ψ,σ2) was then:
[10]
The variance term σ2 was a vector with two
components: σ1
2 for the measurements in
blood, and σ2
2 for the measurements in
exhaled air; these measurements had different
experimental protocols and were thus likely
to have different precisions. 
Interindividual variability was described
by assuming that each component ψik of the
individual TK parameter sets ψi, was distrib-
uted lognormally, with population para-
meters µk and Σ 2kk (in log-space). So the
population model p(ψ|µ,Σ) was given by:
[11]
and
lnψik ∼ N(lnµk,Σ2kk). [12]
The use of a probability distribution to
represent prior knowledge offers a unified
way to account for precise as well as vague
information available before experiments.
There is a large body of literature on the elic-
itation of prior distributions (96,105,106).
When little prior knowledge is available on a
particular parameter value, a noninformative
distribution (i.e., flat-shaped) can be used.
Conversely, in the case of stronger prior
knowledge, the distribution shape, location,
and dispersion parameters should be chosen
to represent that information as appropri-
ately as possible. As stated previously, there is
usually very little prior knowledge of the
parameter values for a particular individual
because information obtainable from the lit-
erature relates more often to average values
or variances for a human population. Within
a population model, such information can be
directly used under the form of prior distrib-
utions for the population parameters µ and Σ
(Figure 4). For example, when a PBTK
model is considered, reference values avail-
able in the literature (71,107) for physiologi-
cal parameters such as blood flows and organ
volumes yield a sound basis for setting up
informative prior distributions. For chemi-
cal-specific parameters, prior information is
often less precise but can still be obtained
from previously published experiments (for
example, in vitro determinations of partition
coefficients or estimates of metabolic para-
meters obtained from in vivo experiments).
In all cases, it is preferable when setting
uncertainties on population parameters to be
conservative and set the prior population
variances higher rather than lower when
there is ambiguity. To stay in physiological
or biochemical plausible ranges, truncated
distributions can be used. 
In the example cited above, all population
parameters were assumed a priori independent
(after scaling functions had been applied). The
prior distribution assigned to each term, µk, of
the population mean µ was a truncated nor-
mal distribution (with parameters Mk and Sk
2
in log-space). So the prior on the mean popu-
lation vector p(µ) was given by:
[13]
and
µk ∼ N(Mk ,Sk
2) [14]
The prior distribution assigned to each popu-
lation variance Σ2kk was an inverse-gamma dis-
tribution with shape parameter equal to one
(to indicate large uncertainties) and scale
parameter ωk
2 (ωk
2 was the prior estimate of







The quantities Mk, Sk
2, and ωk
2 are called
hyperparameters. They directly embody prior
knowledge. For each k, Mk relates to the loca-
tion of the population mean µk, Sk
2 character-
izes the (prior) uncertainty associated with this
location; ωk
2 is used to represent prior beliefs
on the variability of the TK parameter ψk
within the population. Variability and uncer-
tainty were thus formally distinguished. As an
example, consider the metabolic parameter
Vm, which represents the maximum rate of
TETRA metabolism. To reflect the large prior
uncertainty associated with that parameter,
exp(Sk
2) was set to 10, while exp(ωk
2) was set
to 2. This indicates that this parameter was
believed to vary by a factor 2 in the popula-
tion studied, but its true population mean was
uncertain by a factor of 10. It would be diffi-
cult to express such uncertainties without an
explicit hierarchical model.
Finally, the prior distributions assigned
to the experimental error variances σ1
2 and
σ2








sampling. MCMC methods are iterative
sampling schemes that provide direct
approximations to a complex joint posterior
distribution (by random draws from it sets
of parameter values). These methods consist
in constructing a Markov chain that con-
verges, as iterations progress, toward the
posterior distribution, p(θ |y). Various
MCMC methods have been developed to
date; they differ in ways the Markov chain is
constructed. The MH algorithm proved in
our experience to be very efficient in dealing
with Bayesian population TK models.
Briefly, it proceeds as follows: at the begin-
ning, all model unknowns are assigned val-
ues; for example, by sampling from their
respective prior distribution. At each follow-
ing iteration step, each component, θk, of
the parameter vector θ is eventually updated
according to the following acception/rejec-
tion rule: a proposed value, θk´, is sampled
from a “proposal” distribution (e.g., normal,
centered on the current value θk). The joint
posterior density is then computed at θk and
θk´ (up to a proportionality constant, using
Equation 9). Label these two density values
pi and pi´. If the ratio pi´/pi exceeds 1, the
new value θk´ is accepted and replaces θk ;
otherwise, θk´ is accepted only with proba-
bility pi´/pi. In case of rejection of θk´, the
value θk is kept. After (eventually) upating
all components of θ sequentially, their val-
ues are recorded, which completes one itera-
tion of the Markov chain. Many iterations
are typically needed. It has been shown that
under some regularity conditions (i.e., the
Markov chain has to be irreducible, aperi-
odic, and positive recurrent), the chain con-
verges toward the distribution of interest,
i.e., the joint posterior distribution. This
means that after a sufficient number of itera-
tions, the samples generated by such a
process can be considered approximate sam-
ples from p(θ|y), and thus can be used to
make inferences. Implementation details
(e.g., how to choose the proposal distribu-
tion) and techniques to monitor convergence
are well described in the literature
(102,103,109–111) and will not be discussed
here. Briefly, the main desired characteristics
of the proposal distribution are related to
ease of simulation and approximation of the
posterior distribution. 
MCMC methods provide joint distribu-
tions of parameter estimates appropriate for
uncertainty analyses because they account for
the full dependence structure between para-
meter estimates. They are directly usable as
inputs for uncertainty analysis of exposure–
dose relationships.
MCMC methods can actually be viewed
as extensions of the traditional or standard
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(9). Figure 5 is an illustration of MCMC
sampling, compared to simple Monte Carlo
sampling. In the former, the values drawn for
each parameter start from its prior distribu-
tion and converge, as iterations progress, to a
data-adjusted posterior distribution. In the
case of simple Monte Carlo sampling, the val-
ues are always drawn from the prior distribu-
tion. The use of uniform priors in a Bayesian
analysis leads to posteriors strictly propor-
tional to the data likelihood and is equivalent
to the frequentist maximum likelihood esti-
mation. Conversely, if the data do not convey
information about some parameters, the
corresponding posteriors are equal to the priors
and this approach becomes equivalent to stan-
dard Monte Carlo sampling from the priors. 
Analyzing MCMC outputs. MCMC sam-
pling methods provide joint multivariate
samples of parameter values from p(θ|y).
Posterior means, SDs, and quantiles of any
single (or set of) component(s) of θ can be
estimated from these samples by computing
their equivalent in the MCMC output. As an
illustration, we present some results obtained
by calibrating, within a Bayesain hierarchical
framework, the TK model depicted in Figure
2 with the data of Bernillon et al. (55). These
data consisted in concentration–time profiles
of TETRA in air and blood and TCA in
blood and urine, followed for 1 week after
exposure for six volunteers exposed once or
twice to 1 ppm TETRA for 6 hr. 
Histograms can be used to represent the
marginal distribution of individual or popula-
tion parameters. Figure 6A is a histogram of
the estimates of TETRA clearance (mean,
0.17 L/min1; SD, 0.05) for subject A. Figure
6B is a histogram of the distribution of the
population mean of TETRA clearance (mean,
0.16 L/min; SD, 0.03) for the six subjects
studied. The distribution of the population
mean was slightly skewed.
In Bernillon et al. (55), four of the six
subjects studied underwent repeated expo-
sures to TETRA; intraindividual variability
was thus assessed in addition to interindivid-
ual variability. This was achieved by adding
one level to the hierarchy: the first level was
the occasion level (where the observations
were available); at the individual level, occa-
sion-specific parameters were supposed to
vary among exposures around a subject-
specific mean; at the population level, these
subject-specific means were supposed to vary
among individuals. Figure 7 illustrates the
posterior distributions of TETRA clearance at
each of these three levels: occasion, individual
mean, and population mean. For display pur-
poses, the distributions are approximated by
normal (occasion-level parameters) or lognor-
mal (individual or population mean parame-
ters) distributions, whose means and SDs
have been computed on the posterior sam-
ples. A subject's average clearance estimate is
not only influenced by his occasion-specific
estimates but also by the population mean. In
other words, sharing information across indi-
viduals and occasions occurs through the
hierarchical structure. 
In the six-subject sample studied,
interindividual differences in clearance
reached a factor of 1.2 (between subjects A
and C); intraindividual (i.e., interoccasion)
variability reached a factor of 1.3 (subject C).
Inference for a larger population is given by
the size of the posterior interindividual and
intraindividual variances, whose correspond-
ing coefficients of variation were estimated at
33 and 18%, respectively. Using the popula-
tion parameter estimates, it is possible to sim-
ulate additional hypothetical individuals.
Correlations between parameters can also
be studied through correlation matrices (esti-
mated from the MCMC output) or simple
scatterplots. Figure 8 illustrates the correla-
tion between the occasion-specific estimates
of TETRA clearance and the TETRA cen-
tral/air partition coefficient for subject A.
These two parameters are negatively corre-
lated (rˆ = –0.33).
Distributions of model predictions of tox-
icologic interest can also be easily obtained.
Figure 6. Posterior distributions of TETRA clearance for
subject A (A )  and mean population clearance (B )
obtained by calibrating the TK model depicted in Figure
2 to the data of Bernillon et al. (55). The histograms bin
3,000 parameter values sampled from their posterior
distribution.
Figure 5. Illustration of MCMC sampling compared to
simple Monte Carlo sampling. In MCMC sampling (dots),
the values drawn for any parameter θ start from the
prior distribution and converge, as iterations progress, to
a data-adjusted posterior distribution. The posterior den-
sity corresponds to the product of the prior density by
the data likelihood. In the case of simple Monte Carlo
sampling (crosses), the values are always drawn from
the prior distribution. Reproduced from Bois (119) with
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Figure 7. Posterior distributions of TETRA clearance
parameters (occasion-specific, individual mean, and pop-
ulation mean) estimated by calibration of the TK model
depicted on Figure 2 with the data of Bernillon et al.
(55). The population mean distribution is denoted by µ
(thick line), individual means by unsubscripted capitals
A–F (thin lines), occasion-specific distribution values by
subscripted capitals A1–F2 (dashed lines). The mode of
the distribution of the population mean is indicated by
the vertical dashed line.
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Figure 9 gives the posterior distributions of
the fraction of TETRA metabolized by the six
individuals studied, for each occasion of
exposure. These results were obtained by
running the TK model once for each of 3,000
vectors from the MCMC ouptuts for each
individual and occasion-specific parameters
simulating a 1 ppm exposure to TETRA for 6
hr. Large intraindividual variability is
observed following those of TETRA clearance
estimates (Figure 7). Estimates of the fraction
of TETRA metabolized after 1 ppm 6-hr
exposures range from 14% (subject C, occa-
sion 2) to 25% (subject D, occasion 1). This
tends to confirm our results obtained by
extrapolating the results obtained by calibra-
tion of a PBTK model to high-exposure data
(70 and 140 ppm) (38).
After calibration, residual (posterior)
uncertainty is reflected by the range of para-
meter estimates. For each parameter, an esti-
mate of variability is given by the location of
the corresponding (intraindividual, interindi-
vidual) variance parameter. Note that the
variance parameters are themselves affected by
uncertainty.
Sensitivity analyses. Bayesian analyses call
for the specification of prior distributions. A
legitimate question is the sensitivity of the
results (either posterior parameter estimates
or model predictions) with respect to the
choice of those priors. It is therefore recom-
mended that diagnostics of sensitivity be per-
formed. That is quite easy to do after
MCMC sampling, for example, by plotting
and analyzing the correlations between results
and sampled parameter values (39). The prior
assumptions about the parameters that
strongly influence the results can be further
evaluated. It is possible, for example, to study
the effect of changing prior specifications.
The question of sensitivity to the priors
can also be answered generally. Note first that
the choice of priors should always be trans-
parent, i.e., fully stated, to allow useful dis-
cussion of the results. Clearly, the choice of
priors for noninfluential parameters should
not be a problem. For influential parameters,
the priors used can either be vague or infor-
mative (i.e., biologically motivated and
knowledge based) and the posteriors distribu-
tions can be either prior- or data-driven. Four
major cases can therefore be envisioned:
• Both prior and posterior are vague (the
data brought no information). The results
will be prior dependent and more infor-
mation should be acquired either in form
of prior knowledge or additional data.
• The prior is vague, but the posterior is
informative (the data are driving the esti-
mates). In that case, the conclusions
should be robust with respect to the prior.
• The prior is informative and reinforced by
the data (data and prior agree). Here also,
if the data are strongly informative, the
conclusions should be robust. When the
relative weight of prior and data is less
clearcut, further checks of sensitivity are
warranted.
• The prior is informative but the data con-
flict with it. The conclusions will be prior
dependent, but in that case the model, the
prior, and the data should be questioned
to resolve the discrepancy.
Perspectives
The objective of this article was to present a
Bayesian statistical approach to the analysis of
population TK models, which offers a num-
ber of advantages over previously proposed
approaches. The proposed methodology is far
from definitely established and several issues
still must be resolved. For example, several
modeling assumptions are involved, particu-
larly within the population model, that
should be further validated. Hopefully, expe-
rience gained from population analyses using
simpler models can be transposed to PBPK
models. Another task is to reduce the associ-
ated computational burden so as to quickly
explore alternative models. Simple MCMC
samplers can sometimes converge slowly or
even fail to converge. Improved algorithms
recently have been proposed (103,112–115)
and should be tested. In addition, the defini-
tion of prior distributions is not always an
easy task because of data accessibility.
Although it is well known that TK parame-
ters exhibit inter- or intraindividual variabil-
ity in humans (and other species), the only
values readily available and those commonly
used on physiological modeling are reference
values for young Caucasian males. The use of
reference values artificially reduces estimates
of population variance. Information about
population variability may eventually be
found by researching the original publica-
tions, but even these often lack adequate sta-
tistical treatment. Data about the shape of the
distributions are even harder to find. A
database giving population distributions of
important physiological parameter values
together with their correlations is needed.
Such a database would be useful for all types
of physiological modeling and for both toxi-
cants and drugs. Despite these limitations,
experience has been sufficient to demonstrate
that the Bayesian approach provides reason-
able estimates of uncertainty and variability of
TK model parameters and predictions.
Is it worth making the computational
effort implied by such an approach? The
answer to that question is a matter of choice
and scientific judgment. A PBTK model with
standard parameter values might be sufficient
for simple exploratory analyses or for theoret-
ical work on model structure. Alternatively,
for the full analysis of a data set or for risk
assessment purposes, a formal model calibra-
tion along the lines presented here appears
necessary. For example, in a scientific data
analysis context, Smith (116) illustrated, in
the case of occupational exposure to gasoline,
how PBTK and pharmacodynamic models
could be combined with epidemiological data
to evaluate concurrent reasonable hypotheses
concerning mechanisms of toxicity. The sta-
tistical framework described in this article is
convenient in such a setting because distribu-
tions of internal doses are more suitable than
average point estimates in comparing alterna-
tive hypotheses. We have shown how to
extend the methodology for optimal design-
ing of occupational monitoring programs or
TK studies (73). 
This approach is also particularly suited
for risk assessment and decision making. For
example, population extrapolations can be
accomplished if the factors responsible for
heterogeneity (e.g., body weight, breathing
rate, metabolic constants) are among the list
of model parameters. In this case, the popula-
tion distributions obtained for these parame-
ters, from fitting datasets with few volunteers,
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Figure 8. Posterior correlations between TETRA clear-
ance and central/air TETRA partition coefficient esti-
mates (subject A) obtained by calibrating the TK model
depicted in Figure 2 to the data of Bernillon et al. (55).
The dots represent 3,000 pairs of parameter values from
the MCMC outputs. The correlation coefficient is esti-
mated at –0.33.
Figure 9. Prediction of the fraction of TETRA metabo-
lized after an exposure to 1 ppm TETRA for 6 hr by the
six subjects studied at each occasion. Box plots of 3,000
estimates are displayed. Each box encloses 50% of the
predictions; the lines extending from the top and bottom
of each box mark the 10th and 90th percentiles. The line
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can be changed to better reflect the range of
values found in the general population or in
sensitive subpopulations (e.g., children).
Alternatively, if these parameters are measured
for each volunteer and introduced as fixed
covariates during the calibration procedure
(117), they can be replaced by distributions
when making predictions. In this way, the
predictions of interest (e.g., internal metabo-
lite dose, fraction metabolized) can be extrap-
olated beyond the group of individuals used
for calibrating the model. Note that this statis-
tical approach also can be used to calibrate the
other (e.g., fate and transport, cancer effects)
models used in risk assessment (118). 
Finally, one of the challenges of toxico-
logical modeling is the full exploitation of
the numerous datasets collected during epi-
demiological or occupational hygiene studies,
generally in settings in which exposure con-
centrations are unknown. Most of the time,
exposure is represented in a considerably sim-
plified and approximate manner, which can be
misleading. It is possible using the above statis-
tical framework to consider exposure as one of
the estimands. A major problem, however,
resides in accounting fully for the uncertainties
stemming from unknown time-varying expo-
sures. The impact of particular functional form
for the time evolution of exposure has not yet
been thoroughly studied and validated. We are
confident that as progress is made toward
answering such questions, TK modeling will
become a more powerful and widespread tool
for toxicity and risk assessments.
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